ImmunityBio, Inc. (IBRX) Securities Class Action Litigation

Introduction

Securities class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”).

If you purchased or acquired the securities of ImmunityBio during the Class Period, you may move the Court for appointment as lead plaintiff by no later than May 26, 2026.

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

ImmunityBio investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should complete the form below, text or email investorinfo@lchb.com, or call Lieff Cabraser partner Sharon M. Lee at 1-800-541-7358.

Background on the ImmunityBio Securities Class Litigation

ImmunityBio, headquartered in San Diego, California, is a biotechnology company. Anktiva, a bladder cancer drug, is the Company’s lead biologic product.

The action alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendant Patrick Soon-Shiong, ImmunityBio’s Executive Chairman and Global Chief Scientific and Medical Officer, materially misrepresented the capabilities of Anktiva; and (2) consequently, Defendants’ statements about ImmunityBio’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On March 24, 2026, the U.S. Food and Drug Administration (“FDA”) published a warning letter it had sent to ImmunityBio’s CEO on March 13, 2026 claiming that Soon-Shiong promoted Anktiva in a false and/or misleading manner in a podcast and television advertisement for Anktiva. The warning letter objected to Soon-Shiong’s claims about Anktiva’s safety, efficacy, and use, including that Anktiva could be used to treat “all cancers” and that it could be used subcutaneously, despite the fact that it was approved only for the treatment of certain bladder cancer and intravesical use. According to the warning letter, the FDA sent letters to an ImmunityBio subsidiary in September 2025 and January 2026 raising similar concerns regarding the Company’s misleading promotion of Anktiva. On this news, the price of ImmunityBio stock fell $1.98 per share, or 21.1%, from its closing price of $9.40 per share on March 23, 2026, to close at $7.42 per share on March 24, 2026, on extremely heavy trading volume.